NCT04232644View on ClinicalTrials.gov

Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
ADHDNarcolepsy
Interventions
DRUG

ADAIR 10mg IR capsules

manipulated ADAIR IR 3x10 mg capsules

DRUG

Crushed d-amphetamine sulfate IR tablets

crushed d-amphetamine sulfate IR 6 x 5 mg tablets

Trial Locations (1)

M9L 3A2

BioPharma Services Inc., Toronto

All Listed Sponsors
lead

Vallon Pharmaceuticals, Inc.

INDUSTRY

NCT04232644 - Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR) | Biotech Hunter | Biotech Hunter